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Management of 
bronchiolitis
Management of acute bronchiolitis is largely 
supportive.[1] There is currently no proven 
effective therapy other than oxygen for 
hypoxic children (Table 1).[2,3] 
The following supportive treatments 
have been used for the management of 
bronchiolitis: 
• humidified oxygen
• inhaled short-acting bronchodilator therapy 
• nebulised hypertonic saline (3% or 5%)
• corticosteroids: oral or nebulised 
• inhospital use of antiviral treatments, 
e.g. ribavirin in ventilated children
• montelukast 
• antibiotics.
Humidified low-flow oxygen (0.5 - 3.0 L/min) 
applied by nasal prongs is effective for hypoxic 
children. Nasal prongs give a maximum 
inspired oxygen of 28 - 35% except in small 
infants, when higher oxygen concentrations 
may be obtained. Headbox oxygen is an 
alternative and is well tolerated by young 
infants. It requires no humidification, but high 
flow and a mixing device are needed to ensure 
that the correct oxygen concentration is 
delivered. However, there is wastage of oxygen 
and the delivered oxygen concentration 
(FiO2) is unpredictable. Facemask oxygen 
delivers between 28% and 65% oxygen at a 
flow rate of 6 - 10 L/min. In severely hypoxic 
infants who are not ventilated, oxygen should 
be administered using a polymask, which 
enables FiO2 concentrations of 60 - 80% being 
achieved. Oxygen should be weaned when 
the child improves clinically and as hypoxia 
resolves. 
Rapid, short-acting inhaled bronchodilator 
therapy such as albuterol or salbutamol has 
not shown any important clinical benefits in 
the treatment of bronchiolitis.[1,4] A Cochrane 
review (30 trials, 1 992 infants, including inpatient 
and emergency settings) reported no effects 
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Management of acute viral bronchiolitis is largely supportive. There is currently no proven effective therapy other than oxygen for hypoxic 
children. The evidence indicates that there is no routine benefit from inhaled, rapid short-acting bronchodilators, adrenaline or ipratropium 
bromide for children with acute viral bronchiolitis. Likewise, there is no demonstrated benefit from routine use of inhaled or oral corticosteroids, 
inhaled hypertonic saline nebulisation, montelukast or antibiotics. The last should be reserved for children with severe disease, when bacterial 
co-infection is suspected. 
Prevention of respiratory syncytial virus (RSV) disease remains a challenge. A specific RSV monoclonal antibody, palivizumab, 
administered as an intramuscular injection, is available for children at risk of severe bronchiolitis, including premature infants, young 
children with chronic lung disease, immunodeficiency, or haemodynamically significant congenital heart disease. Prophylaxis should be 
commenced at the start of the RSV season and given monthly during the season. The development of an RSV vaccine may offer a more 
effective alternative to prevent disease, for which the results of clinical trials are awaited.
Education of parents or caregivers and healthcare workers about diagnostic and management strategies should include the following: 
bronchio litis is caused by a virus; it is seasonal; it may start as an upper respiratory tract infection with low-grade fever; symptoms are cough 
and wheeze, often with fast breathing; antibiotics are generally not needed; and the condition is usually self limiting, although symptoms 
may occur for up to 4 weeks in some children. 
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Table 1. Therapies that may be 
beneficial in the management of 
bronchiolitis and those that are 
currently not routinely indicated
Beneficial therapies
Humidified oxygen
Therapies not routinely indicated
Bronchodilators
Adrenaline
Steroids (oral, systemic or nebulised)
Montelukast
Physiotherapy
Mucolytics and decongestants
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in oxygen saturation, reduction in hospital admission after outpatient 
treatment, duration of hospitalisation or time to resolution of illness at 
home.[4] Given the potential for adverse side-effects and the cost of these 
treatments, bronchodilators should not be recommended for the routine 
management of bronchiolitis. For studies of adrenaline compared with 
placebo, a Cochrane review (19 studies, 2 256 children) suggested a 
short-term benefit from adrenaline, especially in the first 24 hours 
of the illness.[5] No differences were found for length of hospital stay, 
but there was some evidence that adrenaline was effective for reducing 
the number of hospital admissions.[5] One large, high-quality trial 
suggested that combined treatment with dexamethasone and adrenaline 
may significantly reduce the number of admissions.[5] However, there 
is currently insufficient evidence to support the use of adrenaline for the 
treatment of bronchiolitis among children admitted to hospital. Inhaled 
ipratropium bromide is an ineffective treat ment.[6] 
Conflicting data have been reported for the efficacy of hypertonic 
saline nebulisation administered as nebulised 3% or 5% saline for 
acute bronchiolitis. A 2013 Cochrane review (11 trials, 1 090 child-
ren) reported a reduction in duration of hospital stay and improve-
ment in clinical scores in children who were inpatients, but no 
short-term effects in children in four trials done in an emergency 
unit setting.[7] However, recently the largest reported randomised 
controlled study of nebulised hypertonic saline in acute bronchiolitis: 
randomised controlled trial and economic evaluation (SABRE) in 
hypoxic children, found no difference in outcomes between children 
who received hypertonic saline compared with those who received 
standard care.[8] Other recently published randomised trials have 
also added to the evidence against the use of hypertonic saline in 
bronchiolitis, showing no difference in length of hospital stay, clinical 
scores or improvement in oxygenation compared with children 
receiving normal saline nebulisation or salbutamol.[9-12] The current 
evidence does not demonstrate consistent benefit with the use of 
hypertonic saline; currently, this strategy should therefore not be 
recommended. 
Systemic or inhaled corticosteroids have been shown not to be 
effective in reducing hospital admission or improving clinical scores 
in ambulatory patients.[1,13] However, among inpatients, cortico steroids 
improved clinical scores within the first 12 hours, but did not have 
any effect on length of stay. Therefore, corticosteroids should not be 
routinely recommended.[13] 
Five randomised controlled trials have shown no evidence of benefit 
for inhaled corticosteroids started in the acute phase of bronchiolitis for 
prevention of post-bronchiolitic wheezing.[14] Routine use of syste mic 
or inhaled steroids in the management of bronchiolitis is therefore not 
indicated. 
Montelukast has no effect on the clinical course or outcome of 
bronchiolitis. A study of montelukast (4 mg daily until discharge) 
found that it demonstrated no improvement in the clinical course of 
the disease.[15] In a study of post-bronchiolitis wheeze, montelukast 
did not improve respiratory symptoms of post-RSV bronchiolitis in 
children.[16] 
Similarly, aerosolised ribavirin has been reported not to have any 
significant consistent beneficial effect in the management of bron-
chiolitis.[1,17] 
The use of chest physiotherapy has been shown not to change the 
course of bron chiolitis or its outcome. Chest physiotherapy using 
vibration and percussion techniques does not reduce the length of 
hospital stay or oxygen requirements or improve the severity clinical 
scores in infants with acute bronchiolitis.[18] 
Finally, a Cochrane review of antibiotics compared with placebo 
for bronchiolitis, including two studies of azithromycin com pared 
with placebo, found no difference in length of hospital stay, duration 
of oxygen administration or readmission rates.[19] Antibiotics should 
therefore not be used routinely in bronchiolitis, except in children with 
severe disease in whom bacterial lower respiratory tract infection is 
suspected. 
Prevention of RSV disease in high-risk 
children
The specific RSV monoclonal antibody, palivizumab, is available for 
children at risk of severe bronchiolitis. 
With regard to RSV-associated morbidity, the risk of hospitalisation 
is 5.2/1 000 (4.8 - 5.7) cases.[20] However, this risk rapidly increases 
with decreasing gestational age, being 19.3/1 000 in premature infants 
<29 weeks of gestational age and with congenital heart defects. RSV 
hospitalisation rates are highest at 120.8/1 000 in the first 6 months after 
delivery, declining to 63.2/1 000 at 6 - 12 months of age and to 18.2/1 000 
in the >12-month age group.[20] Similarly, the risk of hospitalisation in 
children with chronic lung disease of prematurity is 562.5/1 000 in 
the <6-month age group, 214.3/1 000 in the 6 - 12-month age group, 
and 73.4/1 000 in those >12 months of age.[20]
Palivizumab has been demonstrated to be effective in reducing 
RSV-related hospi talisation and the need for intensive care unit 
(ICU) admission among all premature infants and those with 
bronchopulmonary dysplasia by 55%, with an adjusted risk reduction 
of 3 - 9% in a Level 1 study.[21] Meta-analysis has confirmed this across 
all populations of preterm infants.[22] This monoclonal antibody has 
also been shown to reduce duration of hospitalisation stay and need for 
oxygen in young children with congenital heart defects.[23] Given the current 
burden of RSV disease, it is estimated that the number needed to treat 
to prevent one hospitalisation from RSV disease in premature infants 
and children with chronic lung disease or congenital heart defects is 
between 16 and 23, which increases sixfold for the prevention of ICU 
admission or death. At the current cost of palivizumab, it is extre mely 
expensive to recommend its widespread use; it is therefore restricted to 
high-risk groups.[24] 
For the prevention of RSV-associated bronchiolitis, the South 
African (SA) guide line for the use of palivizumab recommends that 
it should be restricted for use in the first 6 months of life in high-
risk children, defined as premature infants.[21,22] Furthermore, infants 
with chronic lung disease of prematurity or those with congenital 
heart defects with signi ficant haemodynamic instability (complex 
lesions with pulmonary hypertension) and the premature neonate 
who is a graduate of an ICU and has ongoing respiratory or cardiac 
compromise (diuretic, oxygen or corticosteroid dependent), should be 
covered during the first 24 months of life and during the RSV season. 
RSV prophylaxis may be considered in children with profound 
immunocompromise or pulmonary neuro muscular disease. The 
value of palivizumab is uncertain in children with Down syn drome, 
cystic fibrosis, recurrent wheeze and in nosocomial outbreaks.
It would be appropriate to use palivizumab between January and 
May in high-risk infants (<6 months old), as the RSV season in SA 
is between February and June.[25] The standard dose of 15  mg/kg 
given monthly for 5 months is advocated. All risk groups who are 
resident in hospital and for whom palivizumab is indicated, should 
be initiated on palivizumab in hospital as per guidelines, and not only 
after they are discharged.
Indications for palivizumab 
Indications for palivizumab are the following:
• Premature infants of gestational age of <36 weeks at birth and 
<6 months of age at the start of the RSV season (February). 
Prophylaxis should be continued until the end of the RSV season 
(last dose in May). 
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• Children of any gestation and <24 months 
of age at the start of the RSV season, with 
any of the following: chronic lung disease of 
prematurity, chronic lung disease, primary 
immunodeficiency, haemodynamically sig-
nificant congenital heart disease.
• High-risk premature infants should com-
mence their prophylaxis while still in 
hospital. 
RSV vaccine
While RSV vaccine development was stalled 
for many years owing to the adverse effects 
associated with a formalin-inactivated vac-
cine, substantial progress has recently been 
made in the development of a possible 
vaccine.[26] There are several candidate vac-
cines undergoing Phase 1 trials and two 
undergoing Phase 2 studies (a live atten-
uated vaccine for immunisation of infants 
and an F-protein vaccine for immunisation 
of pregnant women as a strategy to protect 
infants). A Phase 3 study, using a novel 
strategy of immunisation of pregnant 
women in their last trimester of pregnancy, 
has begun. This strategy will potentially 
be effective to prevent disease in young 
infants by transplacental antibody transfer 
and prevention of infection in mothers. 
Such a strategy may have to be coupled 
with vaccination of infants to enable more 
protection of young children for the first two 
years of life.
Parent and caregiver 
education
Management of children with bronchiolitis 
requires that parents or caregivers be edu-
cated about the condition. This is critical 
when children are not admitted to hospital, 
but also after discharge. The key elements of 
an educational message are listed in Table 2.
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Table 2. Key elements of an 
educational message for parents of 
children with bronchiolitis
The condition may start as an upper 
respiratory tract infection with 
low-grade fever
Symptoms are cough and wheeze and 
often fast breathing
Bronchiolitis is caused by a virus; 
antibiotics are not needed
Bronchiolitis is usually self limiting, 
although symptoms may occur for up to 
4 weeks in some children
